Owkin Diagnostics Orb

AI Diagnostics

About our products

Clinically validated digital pathology AI to augment precision oncology workflows

Transform image into action with AI diagnostics

Slider
Significant patterns revealed at the tissue level
Lymphocytes - after
Lymphocytes
H&E
Lymphocytes

Our products enhance patient diagnostics in 3 key ways

RlapsRisk on-screen and tablet view showcasing risk assessment for breast cancer
Pictured here: RlapsRisk BC results in action. Image for presentation only.

First-in-class

Groundbreaking AI diagnostics, accessible across diverse workflows and IT settings

Speed icon
Faster than existing tests

Minutes vs weeks.

Scalable icon
Scalable

Software that runs on standard oncology data.

Seamless icon
Seamless integration

Platform agnostic and plug-and-play.

Cost icon
Cost saving

Compared with traditional tests.

Tissue icon
Tissue sparing

Multiple analyses possible with same tissue sample.

Reproducible icon
Reproducible

Standardized reports at the click of a button.

Explore our products

Our portfolio consists of products for clinical trials or research settings, and IVD solutions that are regulatory-approved and ready for use in clinical routine.
Reset
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
*Certain products are labeled Research Use Only (RUO) based on regional regulatory requirements.

From data to approved medical device, we lead the field in AI diagnostic development

Prix Galien UK Winner 2024

Best Medical Technology

This award highlights Owkin’s dedication to enhancing the efficacy and precision of medical treatments, propelling them as a leader in the healthcare sector.

GlobalData Winner Innovation -AI Diagnostics
Innovation -
AI Diagnostics

For integrating artificial intelligence to enhance diagnostic efficiency and accuracy, revolutionizing the traditional pathology workflow.

GlobalData Winner Product Launches - AI  Diagnostics
Product Launches - AI  Diagnostics

For significantly streamlining the diagnostic process by pre-screening, reducing the number of patients requiring standard MSI testing.

2024 Stevie® Winner for Technology Excellence
3 Stevie® Awards

Technology Breakthrough in Artificial Intelligence

Technology Breakthrough in Healthcare Technology

Grand Stevie for Highest-Rated Nomination of the year

Our building blocks for robust diagnostics

Data

Our vast patient data network lays the foundation for impactful products that meet critical medical needs.
81
leading academic institutions and pathology labs with secured data access.
13
countries that ensure diverse cohorts.
33
therapeutic indications in oncology, immunology and inflammation, with leading KOLs in each field.

AI & data science

We are a world leader in AI and machine learning for digital pathology.
Interpretable
Breakthrough models built on a foundation of 8+ years of R&D with 59 tier 1 peer-reviewed articles.
Generalizable
Maximizing performance and generalizability with world-class foundation models and expertise in model fine-tuning.
Validated
Products undergo robust multicentric and international validations, across a variety of hardware and IT settings.

Regulatory and quality standards

Owkin has regulatory profficiency in navigating the new CE-IVDR and FDA frameworks.
Regulatory expertise
In-house quality management and niche experience in developing AI as fully approved IVDs for clinical use.
International security standards
Robust infrastructure to obtain and maintain ISO certifications.
Notified bodies
Audited by French health authorities certified (ANSM). GMED is our notified body.
Images shown may represent the range of products, or be for illustration purposes only, and may not be an exact representation of the product.
Information last updated on 18th March 2025.